Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.

Fabian Jost-Brinkmann,Münevver Demir,Alexander Wree,Tom Luedde,Sven H Loosen,Tobias Müller,Frank Tacke,Christoph Roderburg,Raphael Mohr

Alimentary pharmacology & therapeutics（2023）

引用 8|浏览28

暂无评分

摘要

Atezolizumab plus bevacizumab showed good efficacy and safety in patients with unresectable HCC and partially advanced liver cirrhosis in a real-world setting. Moreover, the NLR was able to predict response to atezolizumab/bevacizumab treatment and may guide patient selection.

查看译文

关键词

hepatocellular carcinoma,unresectable hepatocellular carcinoma,bevacizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要